3-Acetyl-7-oxo-dehydroepiandrosterone for healing treatment-resistant posttraumatic stress disorder in women: 5 Case reports [2]

Journal of Clinical Psychiatry

Volumn 67, Issue 3, 2006, Pages 493-496

  Sageman, Sharon ^a   Brown, Richard P ^b  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^b College of Physicians and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 ACETYL 7 OXO DEHYDROEPIANDROSTERONE; AMFEBUTAMONE; ANTICONVULSIVE AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; DEXAMPHETAMINE; FLUOXETINE; LAMOTRIGINE; LITHIUM; LORAZEPAM; METHADONE; METHYLPHENIDATE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NEUROLEPTIC AGENT; PAROXETINE; PEMOLINE; PHENTERMINE; PRASTERONE; PRASTERONE SULFATE; PROCHLORPERAZINE; QUETIAPINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TOPIRAMATE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VENLAFAXINE; ZIPRASIDONE;

ADULT; AGITATION; ANAMNESIS; ANXIETY DISORDER; BEHAVIOR THEORY; CLINICAL ARTICLE; CLINICAL FEATURE; COGNITIVE DEFECT; COGNITIVE THERAPY; CONTROLLED STUDY; DEPRESSION; DRUG DOSE REGIMEN; DRUG EFFECT; DYSTHYMIA; DYSTONIA; EMOTIONAL STRESS; FEMALE; HUMAN; HYPERACTIVITY; HYPERTENSION; IRRITABILITY; LETTER; MULTIPLE PERSONALITY; OBESITY; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PSYCHOTHERAPY; SEXUAL ABUSE; SEXUAL DYSFUNCTION; SIDE EFFECT; WEIGHT GAIN;

EID: 33645779539     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/jcp.v67n0323b     Document Type: Letter

References (28)

1. Brady K, Pearlstein T, Asnis GM, et al. Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial. JAMA 2000;283:1837-1844
2. Davidson JR, Rothbaum BO, Vanderkolk BA, et al. Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. Arch Gen Psychiatry 2001;58:485-492
3. Marshall RD, Beebe KL, Oldham M, et al. Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed dose, placebo controlled study. Am J Psychiatry 2001;158:1982-1988
4. Starkman MN, Schteingart DE, Schork MA. Depressed mood and other psychiatric manifestations of Cushing's Syndrome: relationship to hormone levels. Psychosom Med 1981;43:3-18
5. Trethowen WH, Cobb W. Neuropsychiatric aspects of Cushing's Syndrome. AMA Arch Neurol Psychiatry 1952;67:283-309
6. Whelan TB, Schteingart DE, Starkman MN, et al. Neuropsychological deficits in Cushing's Syndrome. J Nerv Ment Dis 1980;168:753-757
7. Starkman MN, Schteingart DE, Schork MA. Cushing's Syndrome after treatment: changes in cortisol and ACTH levels, and amelioration of the depressive syndrome. Psychiatry Res 1986;19:177-188
8. Cohen SI. Cushing's Syndrome: a psychiatric study of 29 patients. Br J Psychiatry 1980;136:120-124
9. Wolkowitz OM, Reus VI. Treatment of depression with antiglucocorticoid drugs. Psychosom Med 1999;61:698-711
10. Schmidt PJ, Daly RC, Bloch M, et al. Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression. Arch Gen Psychiatry 2005;62:154-162
11. Wolkowitz OM, Reus VI, Roberts E, et al. Dehydroepiandrosterone (DHEA) treatment of depression. Biol Psychiatry 1997;41:311-318
12. Wolkowitz OM, Reus VI, Keebler A, et al. Double-blind treatment of major depression with dehydroepiandrosterone. Am J Psychiatry 1999;156:646-649
13. Bloch M, Schmidt PJ, Danaceau MA, et al. Dehydroepiandrosterone treatment of midlife dysthymia. Biol Psychiatry 1999;45:1533-1541
14. Gurnell EM, Chatterjee VK. Dehydroepiandrosterone replacement therapy. Eur J Endocrinol 2001;145:103-106
15. Yen SSC. Dehydroepiandrosterone sulfate and longevity: new clues for an old friend. PNAS 2001;98:8167-8169
16. Kalimi M, Shafagoj Y, Loria R, et al. Antiglucocorticoid effects of dehydroepiandrosterone (DHEA). Mol Cell Biochem 1994;131:99-104
17. Karishma KK, Herbert J. Dehydroepiandrosterone (DHEA) stimulates neurogenesis in the hippocampus of the rat, promotes survival of newly formed neurons and prevents corticosterone-induced suppression. Eur J Neurosci 2002;16:445-453
18. Hampl R, Lapcik O, Hill M, et al. 7-hydroxydehydroepiandrosterone: a natural antiglucocorticoid and a candidate for steroid replacement therapy? Physiol Res 2000;49(suppl 1):107-112
19. Liu YY, Yang N, Kong LN, et al. Effects of 7-oxo-DHEA treatment on the immunoreactivity of BALB/c mice subjected to chronic mild stress. Yao Xue Xue Bao 2003;38:881-884
20. Morfin R, Starka L. Neurosteroid 7-hydroxylation products in the brain. Int Rev Neurobiol 2001;46:79-95
21. Kimonides VG, Khatibi NH, Svendson CN, et al. Dehydroepiandrosterone (DHEA) and DHEA-Sulfate (DHEAS) protect hippocampal neurons against excitatory amino acid induced neurotoxicity. Proc Natl Acad Sci U S A 1998;95:1852-1857
22. Bastianetto S, Ramassamy C, Poirier J, et al. Dehydroepiandrosterone (DHEA) protects hippocampal cells from oxidative stress-induced damage. Brain Res Mol Brain Res 1999;66:35-41
23. Rasmusson AM, Vasek J, Lipschitz DS, et al. An increased capacity for adrenal DHEA release is associated with decreased avoidance and negative mood symptoms in women with PTSD. Neuropsychopharmacology 2004;29:1546-1557
24. Morgan CA, Southwick S, Hazlett G, et al. Relationships among plasma dehydroepiandrosterone sulfate and cortisol levels, symptoms of dissociation, and objective performance in humans exposed to acute stress. Arch Gen Psychiatry 2004;61:819-825
25. Shi J, Schulze S, Lardy H. The effect of 7-oxo-DHEA acetate on memory in young and old C57BL/6mice. Steroids 2000;65:124-129
26. Davidson M, Marwah A, Sawchuk RJ. Safety and pharmacokinetic study with escalating doses of 3-acetyl-7-oxo dehydroepiandrosterone in healthy male volunteers. Clin Invest Med 2000;23:300-310
27. Dean CE. Prasterone (DHEA) and mania. Ann Pharmacother 2000;34:1419-1422
28. Markowitz JS, Carson WH, Jackson CW. Possible dehydroepiandrosterone- induced mania. Biol Psychiatry 1999;45:241-242